Research & Development

From bispecifics and ADCs to better reagents
Wednesday, April 30, 2025
Advances have allowed for the creation of bispecific, ‘Fc-silenced,’ and other specialized antibody reagents tailored to specific research needs. These engineered ... read more
Unlocking cell therapy’s potential
Friday, November 22, 2024
By continuing to crack the code of complex manufacturing, we can move closer to making long-lasting treatments affordable and available to all read more
AAV characterization: current status and future advances
Wednesday, November 20, 2024
For the successful delivery of functional genes to patients, recombinant adenoviral-associated vectors (AAVs) are the most established and leading platform for rare and ... read more
Changing the model of care to advance CAR-T cell therapies
Wednesday, November 20, 2024
Autologous CAR-T cell therapies have already proven effective in treating hematological cancers, spurring extensive research into their potential for a wider range of ... read more
Will the future include CAR-T-similars?
Thursday, October 31, 2024
Evaluating the factors that would support or preclude the birth and expansion of biosimilar versions of CAR-T therapies read more

Legend opens new cell therapy R&D facility in Philly
The 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies.
Thursday, November 13, 2025
Orbital unveils preclinical in vivo CAR-T data for autoimmune disease
OTX-201 achieved full B cell depletion in blood, spleen, and lymph nodes in a non-human primate study.
Wednesday, July 23, 2025
Vertex shares updated data for islet cell therapy in diabetes
All patients who received a full dose of zimislecel achieved ADA-recommended target HbA1c levels and 10/12 patients were insulin free.
Monday, June 23, 2025